サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1428431

C型肝炎の世界市場レポート2024

Hepatitis C Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
C型肝炎の世界市場レポート2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

C型肝炎の市場規模は、今後数年間で急速に成長すると予想されています。 2028年には14.7%の年間複合成長率（CAGR）で1,179億4,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、世界の撲滅の取り組み、検査とスクリーニングの実践の改善、ヘルスケア支出の増加、遠隔医療の統合、および治療の組み合わせの出現に起因すると考えられます。予測期間中に予想される注目すべき動向としては、アクセスしやすく手頃な価格の治療オプションへの焦点、高リスクグループに対する的を絞った取り組み、製剤の進歩、共同イニシアチブとパートナーシップ、C型肝炎管理における遠隔医療とデジタルソリューションの統合などが挙げられます。

C型肝炎市場は、ウイルス感染の増加により成長すると予想されています。体内のウイルスによって引き起こされるウイルス感染症は、ウイルス感染症を根絶し、患者の免疫反応を回復することを目的としたC型肝炎治療によって対処されます。欧州疾病予防管理センターの報告によると、2021年に欧州経済領域（EEA）加盟国29か国でC型肝炎の症例が14,560件報告され、前年の13,914件から増加しました。このウイルス感染の増加は、C型肝炎市場を推進する重要な要因となっています。

肝炎の蔓延はC型肝炎市場の成長に寄与すると予想されます。肝炎は、一般的にウイルス感染、特にA、B、C、D、E型肝炎ウイルスによって引き起こされる炎症性肝臓疾患であり、C型肝炎市場の注目分野です。 2021年 7月の世界保健機関（WHO）のデータによると、推定5,800万人が慢性C型肝炎ウイルス感染症に罹患しており、年間150万人が新たに感染していることが明らかになりました。肝炎の有病率の増加は、C型肝炎市場の成長の主な原動力です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界のC型肝炎市場、タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 慢性C型肝炎
  • 急性C型肝炎
  • その他のタイプ
  • 世界のC型肝炎市場、治療別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 抗ウイルス薬
  • ワクチン
  • 免疫調節薬
  • 手術
  • その他の治療法
  • 世界のC型肝炎市場、診断別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 肝生検
  • 血液検査
  • 画像検査
  • その他の診断
  • 世界のC型肝炎市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院および小売薬局
  • オンライン薬局
  • 世界のC型肝炎市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院
  • クリニック
  • 外来手術センター
  • 診断研究所
  • 研究機関
  • 在宅ケア環境

第7章 地域および国の分析

  • 世界のC型肝炎市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界のC型肝炎市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • C型肝炎市場の競合情勢
  • C型肝炎市場の企業プロファイル
    • Pfizer Inc.
    • Johnson &Johnson Services Inc.
    • F. Hoffman La Roche Ltd.
    • Merck &Co. Inc.
    • AbbVie Inc.

第31章 その他の大手および革新的な企業

  • Bayer AG
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Sumitomo Corporation
  • GlaxoSmithKline plc
  • Takeda Pharmaceutical Company Limited
  • Eli Lilly and Company
  • Boehringer Ingelheim International GmbH.
  • Amgen Inc.
  • Toray Industries Inc.
  • Mylan NV
  • Teva Pharmaceutical Industries Ltd.
  • Astellas Pharma Inc.
  • Biogen Inc.
  • Vertex Pharmaceuticals Incorporated

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r14276

Hepatitis C is a viral infection that affects the liver, leading to inflammation and gradual destruction of liver tissues. The primary cause of hepatitis C is an infection with the hepatitis C virus (HCV), a virus transmitted through contaminated blood. The most common mode of transmission is through the sharing of needles or other equipment used for injecting drugs.

The main types of hepatitis C are chronic hepatitis C, acute hepatitis C, and others. Chronic hepatitis C denotes a persistent infection caused by the hepatitis C virus, occurring when the body is unable to effectively combat the virus. Treatment options for chronic hepatitis C include antiviral drugs, vaccines, immune modulator drugs, surgery, and others. The diagnostic process typically involves liver biopsy, blood tests, imaging tests, and others, with distribution through hospital and retail pharmacies, as well as online pharmacies. End-users encompass hospitals, clinics, ambulatory surgical centers, diagnostic laboratories, research institutes, and home care settings.

The hepatitis C market research report is one of a series of new reports from The Business Research Company that provides hepatitis C market statistics, including hepatitis C industry global market size, regional shares, competitors with a hepatitis C market share, detailed hepatitis C market segments, market trends, and opportunities, and any further data you may need to thrive in the hepatitis C industry. This hepatitis C market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hepatitis c market size has grown rapidly in recent years. It will grow from $59.58 billion in 2023 to $68.25 billion in 2024 at a compound annual growth rate (CAGR) of 14.5%. The growth observed in the historical period can be attributed to factors such as blood transfusion practices, injection drug use, limited treatment options, and the development of direct-acting antivirals (DAAs).

The hepatitis c market size is expected to see rapid growth in the next few years. It will grow to $117.94 billion in 2028 at a compound annual growth rate (CAGR) of 14.7%. The anticipated growth in the forecast period can be attributed to global elimination efforts, improved testing and screening practices, increasing healthcare spending, the integration of telemedicine, and the emergence of therapeutic combinations. Notable trends expected in the forecast period include a focus on accessible and affordable treatment options, targeted efforts for high-risk groups, advancements in drug formulations, collaborative initiatives and partnerships, as well as the integration of telehealth and digital solutions in hepatitis C management.

The hepatitis C market is anticipated to experience growth driven by an increase in viral infections. Viral infections, caused by viruses within the body, are addressed by hepatitis C treatment, which aims to eradicate the viral infection and restore the immune response in patients. As reported by the European Centre for Disease Prevention and Control, 14,560 cases of hepatitis C were reported in 29 European Economic Area (EEA) member states in 2021, marking an increase from the previous year's 13,914 cases. This rise in viral infections serves as a significant factor propelling the hepatitis C market.

The prevalence of hepatitis is expected to contribute to the growth of the hepatitis C market. Hepatitis, an inflammatory liver condition commonly caused by viral infections, particularly hepatitis viruses A, B, C, D, and E, is a focus area for the Hepatitis C market. Data from the World Health Organization (WHO) in July 2021 revealed an estimated 58 million individuals with chronic hepatitis C virus infection, experiencing 1.5 million new infections annually. The increasing prevalence of hepatitis is a key driver for the growth of the hepatitis C market.

A noteworthy trend gaining popularity in the hepatitis C market is the advancement in diagnostic technologies. Major companies in the market are adopting new technologies to maintain their market positions. In July 2022, F. Hoffmann-La Roche Ltd. introduced the Elecsys HCV Duo immunoassay, allowing the independent and simultaneous determination of hepatitis C virus (HCV) antigen and antibody status from a single human plasma or serum sample. The test aids in identifying patients recovering from or exhibiting symptoms of chronic infection, potentially leading to other diseases such as liver cancer.

Strategic alliances are a focal point for major companies operating in the hepatitis C market to strengthen their positions. In July 2021, Medecins Sans Frontieres (MSF), FIND, and Treatment Action Group joined forces to address disparities in access to diagnostics and treatment for the hepatitis C virus (HCV) in low- and middle-income countries (LMICs). The partnership emphasizes the significance of collaborative efforts to save lives, reduce costs in national budgets, and prove cost-effective.

In September 2022, Gilead Sciences Inc. partnered with Brigham and Women's Hospital, Harvard Medical School, and Beth Israel Deaconess Medical Center for Health Advancement in Vietnam (HAIVN). This public-private initiative aims to improve the management of viral hepatitis in Vietnam and the Philippines, aligning with the global goal of hepatitis C elimination by 2030. The collaboration involves institutions such as Brigham and Women's Hospital and Beth Israel Deaconess Medical Center in the U.S. and Harvard Medical School.

Major companies operating in the hepatitis c market report are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffman La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Sumitomo Corporation , GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH., Amgen Inc., Toray Industries Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Aurobindo Pharma Ltd., Cipla Ltd., Lupin Limited, Cadila Healthcare Ltd., LEO Pharma A/S, Biocon Limited, Kadmon Holdings Inc.

North America was the largest region in the hepatitis C market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hepatitis c market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the hepatitis c market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The hepatitis C market consists of revenues earned by entities by providing shunt procedures, hepatic resection, and biopsies. The market value includes the value of related goods sold by the service provider or included within the service offering. The hepatitis C market also includes sales of ledipasvir and sofosbuvir, non-structural protein 5B (NS5B) polymerase inhibitors, non-structural protein 5A (NS5A) replication complex inhibitors, and elbasvir and grazoprevir drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hepatitis C Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hepatitis c market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hepatitis c ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hepatitis c market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Type: Chronic Hepatitis C; Acute Hepatitis C; Other Types
  • 2) By Treatment: Antiviral Drugs; Vaccine; Immune Modulator Drugs; Surgery; Other Treatments
  • 3) By Diagnosis: Liver Biopsy; Blood Tests; Imaging Tests; Other Diagnosis
  • 4) By Distribution Channel: Hospital And Retail Pharmacies; Online Pharmacies
  • 5) By End-User: Hospitals; Clinics; Ambulatory Surgical Centers; Diagnostic Laboratories; Research Institutes; Home Care Settings
  • Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F. Hoffman La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Hepatitis C Market Characteristics

3. Hepatitis C Market Trends And Strategies

4. Hepatitis C Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Hepatitis C Market Size and Growth

  • 5.1. Global Hepatitis C Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Hepatitis C Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Hepatitis C Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Hepatitis C Market Segmentation

  • 6.1. Global Hepatitis C Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Chronic Hepatitis C
  • Acute Hepatitis C
  • Other Types
  • 6.2. Global Hepatitis C Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Antiviral Drugs
  • Vaccine
  • Immune Modulator Drugs
  • Surgery
  • Other Treatments
  • 6.3. Global Hepatitis C Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Liver Biopsy
  • Blood Tests
  • Imaging Tests
  • Other Diagnosis
  • 6.4. Global Hepatitis C Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital And Retail Pharmacies
  • Online Pharmacies
  • 6.5. Global Hepatitis C Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Diagnostic Laboratories
  • Research Institutes
  • Home Care Settings

7. Hepatitis C Market Regional And Country Analysis

  • 7.1. Global Hepatitis C Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Hepatitis C Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Hepatitis C Market

  • 8.1. Asia-Pacific Hepatitis C Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Hepatitis C Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Hepatitis C Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Hepatitis C Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Hepatitis C Market

  • 9.1. China Hepatitis C Market Overview
  • 9.2. China Hepatitis C Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Hepatitis C Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Hepatitis C Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Hepatitis C Market

  • 10.1. India Hepatitis C Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Hepatitis C Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Hepatitis C Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Hepatitis C Market

  • 11.1. Japan Hepatitis C Market Overview
  • 11.2. Japan Hepatitis C Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Hepatitis C Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Hepatitis C Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Hepatitis C Market

  • 12.1. Australia Hepatitis C Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Hepatitis C Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Hepatitis C Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Hepatitis C Market

  • 13.1. Indonesia Hepatitis C Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Hepatitis C Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Hepatitis C Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Hepatitis C Market

  • 14.1. South Korea Hepatitis C Market Overview
  • 14.2. South Korea Hepatitis C Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Hepatitis C Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Hepatitis C Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Hepatitis C Market

  • 15.1. Western Europe Hepatitis C Market Overview
  • 15.2. Western Europe Hepatitis C Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Hepatitis C Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Hepatitis C Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Hepatitis C Market

  • 16.1. UK Hepatitis C Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Hepatitis C Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Hepatitis C Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Hepatitis C Market

  • 17.1. Germany Hepatitis C Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Hepatitis C Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Hepatitis C Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Hepatitis C Market

  • 18.1. France Hepatitis C Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Hepatitis C Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Hepatitis C Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Hepatitis C Market

  • 19.1. Italy Hepatitis C Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Hepatitis C Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Hepatitis C Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Hepatitis C Market

  • 20.1. Spain Hepatitis C Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Hepatitis C Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Hepatitis C Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Hepatitis C Market

  • 21.1. Eastern Europe Hepatitis C Market Overview
  • 21.2. Eastern Europe Hepatitis C Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Hepatitis C Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Hepatitis C Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Hepatitis C Market

  • 22.1. Russia Hepatitis C Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Hepatitis C Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Hepatitis C Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Hepatitis C Market

  • 23.1. North America Hepatitis C Market Overview
  • 23.2. North America Hepatitis C Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Hepatitis C Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Hepatitis C Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Hepatitis C Market

  • 24.1. USA Hepatitis C Market Overview
  • 24.2. USA Hepatitis C Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Hepatitis C Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Hepatitis C Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Hepatitis C Market

  • 25.1. Canada Hepatitis C Market Overview
  • 25.2. Canada Hepatitis C Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Hepatitis C Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Hepatitis C Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Hepatitis C Market

  • 26.1. South America Hepatitis C Market Overview
  • 26.2. South America Hepatitis C Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Hepatitis C Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Hepatitis C Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Hepatitis C Market

  • 27.1. Brazil Hepatitis C Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Hepatitis C Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Hepatitis C Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Hepatitis C Market

  • 28.1. Middle East Hepatitis C Market Overview
  • 28.2. Middle East Hepatitis C Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Hepatitis C Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Hepatitis C Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Hepatitis C Market

  • 29.1. Africa Hepatitis C Market Overview
  • 29.2. Africa Hepatitis C Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Hepatitis C Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Hepatitis C Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Hepatitis C Market Competitive Landscape And Company Profiles

  • 30.1. Hepatitis C Market Competitive Landscape
  • 30.2. Hepatitis C Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Johnson & Johnson Services Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. F. Hoffman La Roche Ltd.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Merck & Co. Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. AbbVie Inc.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Hepatitis C Market Other Major And Innovative Companies

  • 31.1. Bayer AG
  • 31.2. Novartis AG
  • 31.3. Bristol-Myers Squibb Company
  • 31.4. Sumitomo Corporation
  • 31.5. GlaxoSmithKline plc
  • 31.6. Takeda Pharmaceutical Company Limited
  • 31.7. Eli Lilly and Company
  • 31.8. Boehringer Ingelheim International GmbH.
  • 31.9. Amgen Inc.
  • 31.10. Toray Industries Inc.
  • 31.11. Mylan N.V.
  • 31.12. Teva Pharmaceutical Industries Ltd.
  • 31.13. Astellas Pharma Inc.
  • 31.14. Biogen Inc.
  • 31.15. Vertex Pharmaceuticals Incorporated

32. Global Hepatitis C Market Competitive Benchmarking

33. Global Hepatitis C Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Hepatitis C Market

35. Hepatitis C Market Future Outlook and Potential Analysis

  • 35.1 Hepatitis C Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Hepatitis C Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Hepatitis C Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer